裸体临时Spur支架系统治疗胫动脉后早期血管回缩:DEEPER OUS血管回缩子研究结果
本研究评估可回收支架治疗(RST)后胫动脉急性血管回缩的发生率及短期影响。38例患者40处病变在RST后即刻及15分钟后造影,回缩定义为15分钟后管腔直径减少≥10%。42.5%的血管出现回缩,6个月通畅率在回缩与无回缩病变间无显著差异(81.8% vs 89.5%),未发现回缩与6个月通畅率相关。
要点
- RST治疗后42.5%的胫动脉血管出现早期回缩(15分钟管腔直径减少≥10%)。
- 回缩与无回缩病变6个月通畅率无显著差异(81.8% vs 89.5%),无回缩组有通畅趋势。
- 回缩与合并症或病变特征(包括钙化)无显著相关性,钙化与通畅率亦无相关性。
核心结论
- RST治疗的血管中42.5%出现血管回缩,而既往球囊血管成形术报道的回缩率高达97%,提示RST可能影响血管回缩。
- 本探索性研究未证明血管回缩与6个月通畅率之间存在相关性。
研究设计与样本
- 本研究为DEEPER OUS血管回缩子研究,纳入38例患者(40处病变;33例男性[87%];平均[SD]年龄75.3[8.2]岁;26例[68.4%]患糖尿病)。
- 患者接受Spur外周可回收支架系统(Spur)行可回收支架治疗(RST),治疗后即刻及15分钟后行血管造影。
- 血管回缩定义为15分钟后管腔直径减少≥10%,并采用晚期管腔丢失法、亚段晚期管腔丢失法及最小段对同段法进一步分析。
主要发现
- 42.5%的血管出现回缩;治疗前13处病变(32.5%)为完全闭塞,平均病变长度64.7±30.4 mm,27.5%(11/40)为中重度钙化,平均治疗病变长度97.8±39.6 mm。
- 可评估的双功超声病变中,86.7%的血管(26/30)在6个月时通畅。
- 回缩病变与无回缩病变的6个月通畅率无显著差异(81.8% vs 89.5%),无回缩组有通畅趋势。
- 2处病变出现功能性回缩(急性血管痉挛),均在6个月时通畅。
- 回缩与合并症或病变特征(包括钙化)无统计学显著相关性,钙化与通畅率亦无相关性。
关键数值与推荐
- 血管回缩定义为治疗后15分钟管腔直径较基线减少≥10%。
- 功能性回缩(急性血管痉挛)定义为15分钟治疗后最小管腔直径(MLD)与基线相比无显著变化。
临床怎么用
- 可回收支架治疗可能替代切割球囊和刻痕球囊等器械,用于确定性(药物)治疗前的血管准备。
- 可回收支架治疗补充了现有血管准备策略,以遵循「不留置异物」的理念。
- 临时可回收支架可改变血管顺应性并可能释放抗增殖药物,代表一种新的介入理念。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Vessel recoil is a common phenomenon occurring in the tibial vessels following balloon angioplasty. This study examined the occurrence and short-term impact of acute vessel recoil in a subset of patients treated with retrievable scaffold therapy (RST) via the Spur Peripheral Retrievable Scaffold System (Spur). METHODS: Patients with tibial disease underwent angiography immediately following RST, and then 15 minutes post-treatment. Vessel recoil was defined as a ≥10% decrease in lumen diameter after 15 minutes. Recoil was further analyzed by late lumen loss method, subsegmental late lumen loss method, and smallest segment to same segment method. Patient and vessel characteristics were evaluated. Functional recoil (acute vessel spasm), defined as no significant change in minimal lumen diameter (MLD) at baseline compared with 15 minutes post-treatment, was also evaluated. RESULTS: Of the 38 patients (40 lesions; 33 men [87%]; mean [SD] age 75.3 [8.2] years; 26 (68.4%) with diabetes mellitus); recoil was noted in 42.5% of vessels. Prior to treatment, 13 lesions (32.5%) were total occlusions, the mean lesion length was 64.7±30.4 mm, and 27.5% (11/40) were moderate or severely calcified. Mean treated lesion length was 97.8±39.6 mm. For lesions evaluable by duplex ultrasound, 86.7% of vessels (26/30) were patent at 6 months. There was no significant difference in patency between lesions with recoil and lesions without recoil (81.8% vs 89.5%); there was a trend toward patency in the non-recoil group. Two lesions had functional recoil (acute vessel spasm) and were patent at 6 months. There was no statistically significant correlation of recoil to comorbidities or lesion characteristics, including calcification, for which there was also no correlation to patency. CONCLUSION: Vessel recoil was noted in 42.5% of vessels treated with RST, whereas previous published rates with balloon angioplasty demonstrated vessel recoil up to 97%, suggesting that RST may impact vessel recoil. This exploratory study did not demonstrate a correlation between vessel recoil and patency at 6 months.Clinical ImpactRetrievable scaffold therapy may replace scoring devices and cutting devices for vessel preparation before definite (drug) therapy. Retrievable scaffold therapy supplements already established vessel preparation strategies in order to follow the concept of leaving nothing behaind. A temporary retrievable scaffold for changing vessel compliance and potentially releasing antiproliferative drugs represents a new interventional concept.
引用
- Zeller T, Zhang Z, Parise H, et al. Early Tibial Vessel Recoil Following Treatment With the Bare Temporary Spur Stent System: Results From the DEEPER OUS Vessel Recoil Substudy. J Endovasc Ther. 2024. PMID: 39305087. doi:10.1177/15266028241280685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。